Welch & Forbes LLC lowered its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 1.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,100 shares of the company’s stock after selling 230 shares during the period. Welch & Forbes LLC’s holdings in Teva Pharmaceutical Industries Limited were worth $402,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the stock. Alliancebernstein L.P. raised its stake in Teva Pharmaceutical Industries Limited by 7.3% in the first quarter. Alliancebernstein L.P. now owns 8,617,143 shares of the company’s stock worth $276,524,000 after buying an additional 587,286 shares during the last quarter. Camber Capital Management LLC raised its stake in Teva Pharmaceutical Industries Limited by 10.4% in the first quarter. Camber Capital Management LLC now owns 5,216,450 shares of the company’s stock worth $167,396,000 after buying an additional 492,000 shares during the last quarter. Renaissance Technologies LLC raised its stake in Teva Pharmaceutical Industries Limited by 122.4% in the first quarter. Renaissance Technologies LLC now owns 4,817,763 shares of the company’s stock worth $154,602,000 after buying an additional 2,651,900 shares during the last quarter. State Street Corp raised its stake in Teva Pharmaceutical Industries Limited by 15.9% in the first quarter. State Street Corp now owns 4,530,768 shares of the company’s stock worth $145,390,000 after buying an additional 621,795 shares during the last quarter. Finally, State of Wisconsin Investment Board raised its stake in Teva Pharmaceutical Industries Limited by 0.8% in the first quarter. State of Wisconsin Investment Board now owns 1,952,150 shares of the company’s stock worth $62,644,000 after buying an additional 15,140 shares during the last quarter. 56.27% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the consensus estimate of $1.06 by $0.07. The company had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business’s revenue was up 12.9% on a year-over-year basis. During the same quarter last year, the firm earned $1.25 EPS.

ILLEGAL ACTIVITY NOTICE: This story was posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/07/welch-forbes-llc-decreases-position-in-teva-pharmaceutical-industries-limited-nyseteva.html.

A number of research firms have weighed in on TEVA. Cantor Fitzgerald set a $31.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a report on Thursday, June 22nd. Vetr lowered shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $31.05 target price on the stock. in a report on Thursday, June 22nd. CIBC reissued a “market perform” rating on shares of Teva Pharmaceutical Industries Limited in a report on Thursday. Credit Suisse Group set a $39.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a report on Thursday. Finally, Sanford C. Bernstein lowered shares of Teva Pharmaceutical Industries Limited from an “outperform” rating to a “market perform” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, twenty-two have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Teva Pharmaceutical Industries Limited presently has a consensus rating of “Hold” and a consensus price target of $39.81.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.